APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1/PD-L1 Checkpoint Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

PD-1/PD-L1 Checkpoint Inhibitors Industry Research Report 2026

28 December 2025124 pages

Choose your research edition.

Industry ResearchPD-1/PD-L1 Checkpoint Inhibitors Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1/PD-L1 Checkpoint Inhibitors Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PD-1/PD-L1 Checkpoint Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global PD-1/PD-L1 Checkpoint Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for PD-1/PD-L1 Checkpoint Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for PD-1/PD-L1 Checkpoint Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of PD-1/PD-L1 Checkpoint Inhibitors include Merck, Junshi Biosciences, Pfizer, Hengrui Pharmaceuticals, Roche, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global PD-1/PD-L1 Checkpoint Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PD-1/PD-L1 Checkpoint Inhibitors Market by Company

Merck

Junshi Biosciences

Pfizer

Hengrui Pharmaceuticals

Roche

Regeneron Pharmaceuticals

Bristol Myers Squibb

AstraZeneca

PD-1/PD-L1 Checkpoint Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1/PD-L1 Checkpoint Inhibitors Segment by Application

Gastric Cancer

Squamous Cell Skin Cancer

Melanoma

Non-small Cell Lung Cancer

Other

PD-1/PD-L1 Checkpoint Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1/PD-L1 Checkpoint Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1/PD-L1 Checkpoint Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1/PD-L1 Checkpoint Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of PD-1/PD-L1 Checkpoint Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of PD-1/PD-L1 Checkpoint Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of PD-1/PD-L1 Checkpoint Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PD-1/PD-L1 Checkpoint Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) of Manufacturers (2021-2026) Table 7. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global PD-1/PD-L1 Checkpoint Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Product Type & Application Table 14. Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global PD-1/PD-L1 Checkpoint Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Merck Company Information Table 19. Merck Business Overview Table 20. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 22. Merck Recent Developments Table 23. Junshi Biosciences Company Information Table 24. Junshi Biosciences Business Overview Table 25. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 27. Junshi Biosciences Recent Developments Table 28. Pfizer Company Information Table 29. Pfizer Business Overview Table 30. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 32. Pfizer Recent Developments Table 33. Hengrui Pharmaceuticals Company Information Table 34. Hengrui Pharmaceuticals Business Overview Table 35. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 37. Hengrui Pharmaceuticals Recent Developments Table 38. Roche Company Information Table 39. Roche Business Overview Table 40. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 42. Roche Recent Developments Table 43. Regeneron Pharmaceuticals Company Information Table 44. Regeneron Pharmaceuticals Business Overview Table 45. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 47. Regeneron Pharmaceuticals Recent Developments Table 48. Bristol Myers Squibb Company Information Table 49. Bristol Myers Squibb Business Overview Table 50. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 52. Bristol Myers Squibb Recent Developments Table 53. AstraZeneca Company Information Table 54. AstraZeneca Business Overview Table 55. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 57. AstraZeneca Recent Developments Table 58. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026) & (K Units) Table 60. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2021-2026) Table 61. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2027-2032) & (K Units) Table 62. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2027-2032) Table 63. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 64. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021-2026) Table 65. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 66. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2027-2032) Table 67. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 69. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 70. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 71. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 74. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 75. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 79. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 80. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 82. South America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 84. South America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 85. South America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 86. South America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 89. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 90. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 92. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units) Table 93. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2027-2032) & (K Units) Table 94. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026) Table 95. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2027-2032) Table 96. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 97. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 98. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2026) Table 99. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2027-2032) Table 100. Global PD-1/PD-L1 Checkpoint Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 101. Global PD-1/PD-L1 Checkpoint Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 102. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026) & (K Units) Table 103. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2027-2032) & (K Units) Table 104. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026) Table 105. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2027-2032) Table 106. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 107. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 108. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2026) Table 109. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2027-2032) Table 110. Global PD-1/PD-L1 Checkpoint Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 111. Global PD-1/PD-L1 Checkpoint Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. PD-1/PD-L1 Checkpoint Inhibitors Distributors List Table 115. PD-1/PD-L1 Checkpoint Inhibitors Customers List Table 116. PD-1/PD-L1 Checkpoint Inhibitors Industry Trends Table 117. PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers Table 118. PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. PD-1/PD-L1 Checkpoint Inhibitors Product Image Figure 5. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (2021-2032) & (K Units) Figure 8. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 9. PD-1 Inhibitors Product Image Figure 10. PD-L1 Inhibitors Product Image Figure 11. Gastric Cancer Product Image Figure 12. Squamous Cell Skin Cancer Product Image Figure 13. Melanoma Product Image Figure 14. Non-small Cell Lung Cancer Product Image Figure 15. Other Product Image Figure 16. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 PD-1/PD-L1 Checkpoint Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region in 2025 Figure 22. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region in 2025 Figure 23. North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country in 2025 Figure 24. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country in 2025 Figure 30. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 31. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2032) Figure 32. Germany PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country in 2025 Figure 43. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2032) Figure 45. China PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country in 2025 Figure 54. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 55. South America PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2032) Figure 56. Brazil PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country in 2025 Figure 60. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Country (2021-2032) Figure 62. Egypt PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries PD-1/PD-L1 Checkpoint Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2032) Figure 68. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2032) Figure 69. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Type (2021-2032) Figure 70. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2032) Figure 71. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2032) Figure 72. Global PD-1/PD-L1 Checkpoint Inhibitors Price (US$/Unit) by Application (2021-2032) Figure 73. PD-1/PD-L1 Checkpoint Inhibitors Value Chain Figure 74. PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Gastric Cancer
  • Squamous Cell Skin Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Other
Companies covered
  • Merck
  • Junshi Biosciences
  • Pfizer
  • Hengrui Pharmaceuticals
  • Roche
  • Regeneron Pharmaceuticals
  • Bristol Myers Squibb
  • AstraZeneca

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales (2021-2032)
  5. 2.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (2021-2032)
  6. 2.3 PD-1/PD-L1 Checkpoint Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 PD-1 Inhibitors
  9. 2.3.3 PD-L1 Inhibitors
  10. 2.4 PD-1/PD-L1 Checkpoint Inhibitors by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Gastric Cancer
  13. 2.4.3 Squamous Cell Skin Cancer
  14. 2.4.4 Melanoma
  15. 2.4.5 Non-small Cell Lung Cancer
  16. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global PD-1/PD-L1 Checkpoint Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Established Date
  9. 3.9 Global PD-1/PD-L1 Checkpoint Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Merck
  2. 4.1.1 Merck Company Information
  3. 4.1.2 Merck Business Overview
  4. 4.1.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  6. 4.1.5 Merck Recent Developments
  7. 4.2 Junshi Biosciences
  8. 4.2.1 Junshi Biosciences Company Information
  9. 4.2.2 Junshi Biosciences Business Overview
  10. 4.2.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  12. 4.2.5 Junshi Biosciences Recent Developments
  13. 4.3 Pfizer
  14. 4.3.1 Pfizer Company Information
  15. 4.3.2 Pfizer Business Overview
  16. 4.3.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  18. 4.3.5 Pfizer Recent Developments
  19. 4.4 Hengrui Pharmaceuticals
  20. 4.4.1 Hengrui Pharmaceuticals Company Information
  21. 4.4.2 Hengrui Pharmaceuticals Business Overview
  22. 4.4.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  24. 4.4.5 Hengrui Pharmaceuticals Recent Developments
  25. 4.5 Roche
  26. 4.5.1 Roche Company Information
  27. 4.5.2 Roche Business Overview
  28. 4.5.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  30. 4.5.5 Roche Recent Developments
  31. 4.6 Regeneron Pharmaceuticals
  32. 4.6.1 Regeneron Pharmaceuticals Company Information
  33. 4.6.2 Regeneron Pharmaceuticals Business Overview
  34. 4.6.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  36. 4.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 4.7 Bristol Myers Squibb
  38. 4.7.1 Bristol Myers Squibb Company Information
  39. 4.7.2 Bristol Myers Squibb Business Overview
  40. 4.7.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  42. 4.7.5 Bristol Myers Squibb Recent Developments
  43. 4.8 AstraZeneca
  44. 4.8.1 AstraZeneca Company Information
  45. 4.8.2 AstraZeneca Business Overview
  46. 4.8.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  48. 4.8.5 AstraZeneca Recent Developments
5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Scenario by Region
  1. 5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 PD-1/PD-L1 Checkpoint Inhibitors Value Chain Analysis
  2. 8.1.1 PD-1/PD-L1 Checkpoint Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process
  5. 8.2 PD-1/PD-L1 Checkpoint Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors
  8. 8.2.3 PD-1/PD-L1 Checkpoint Inhibitors Customers
9 Global PD-1/PD-L1 Checkpoint Inhibitors Analyzing Market Dynamics
  1. 9.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends
  2. 9.2 PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers
  3. 9.3 PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges
  4. 9.4 PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst